Objective To explore the changes of plasma redox status in patients with coronary heart disease and its clinical implications. Methods One hundred and forty-four patients suspected with coronary heart disease were divided into three groups according to the results of coronary arteriography. Coronary heart disease group (n= 59, group A), coronary atherosclerosis group (n=53, group B), and normal coronary group (n=32, group C). The plasma glutathione (reduced form GSH and oxidized form GSSG) ,oxidized low density hpoprotein cholesterol(ox-LDL-C) and malondialdehyde (MDA) were measured in all patients. The GSH/GSSG redox potential were calculat-ed according to Nernst equation,and their correlation with the severity of coronary artery stenosis and oxLDL-C was analyzed. Results Along with the severity of coronary artery stenosis (from Group C to Group A), GSH, GSH/ GSSG gradually reduced (respectively (321.27±56.80)μmol/L, (309.52±44.97) μmol/L, ( 285.71±38.38) μmol/L;10.56±1.70,9.86±1.58,8.65±1.18 ;F=29.49 and 26.18,P<0.05), whereas GSH/GSSG redox po-tential gradually increased ( (- 142.23±1.35) mV, (-140.41±1.13) mV, (-136.61±1.21 ) mV;F =20.69,P <0.05 )) and redox status deviated to oxidization. The products of oxidative stress oxLDL-C and MDA also increased significantly along with the severity of coronary artery stenosis (respectively (417.24±126.64 ) μg/L, (557.45±171.85) μg/L, (691.96±203, 56 ) μg/L;(2.39±1.24) μmol/L, (3.25±1.37 ) μmol/L, (4.39± 1.52) μmol/L;F=26.28 and 25.39,P<0.05). GSH/GSSG redox potential was positively correlated with oxLDL-C (r=0.798,P<0.05). Conclusions The imbalance of plasma redox status and deviating to oxidization may be closely related with the development and progress of atherosclerosis.

OBJECTIVE: To explore the effects of Xuezhikang Capsules (ZXKC) and probucol on blood lipids, vascular endothelial functions and redox status in patients with coronary heart disease. METHODS: One hundred and twelve patients with coronary heart disease were randomly divided into XZKC-treated group and probucol-treated group, 56 in each. Before and after 8-week treatment, the blood levels of total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), nitric oxide (NO), endothelin-1 (ET-1), reduced glutathione (GSH) and oxidized glutathione (GSSG) were all measured in both groups. The GSH/GSSG redox potential (Eh) was calculated according to the Nernst equation. RESULTS: In the XZKC-treated group, the blood levels of TC, LDL-C and TG were significantly decreased after 8-week treatment as compared with those before treatment. The blood levels of TC and LDL-C were also significantly decreased in the probucol-treated group as compared with those before treatment. In the XZKC-treated group, the blood levels of ET-1 and GSSG and the GSH/GSSG Eh after treatment were all significantly lower than those before treatment, whereas the blood levels of GSH and NO, the NO/ET-1 ratio, and the GSH/GSSG ratio after treatment were all significantly higher than those before treatment. CONCLUSION: The XZKC or probucol treatment can yield a significant decrease in blood lipids in patients with coronary heart disease. Furthermore, XZKC exerts effective protection on vascular endothelial function, and can make GSH/GSSG redox status shift towards deoxidation.

PurposeThe bone flare phenomena has been well described on bone scintigraphy for efficacy monitoring up to now, but our knowledge has been rarely described on MSCT, the phenomena may be erroneously classiifed as disease progression. This article intends to evaluate the existence and CT features of bone flare phenomena of metastatic bone disease in lung cancer patients treated with ibandronate, to raise awareness of this phenomenon.Materials and Methods The clinical and image data of 45 patients with bone metastases of lung cancer were retrospectively analyzed prior to treatment and 3, 6 months after treatment, the change of CT value and CT features 3 months after treatment between bone flare phenomena group, progressive disease group 1 and progressive disease group 2 were compared.Results The incidence of bone flare phenomena was 6.7% (3/45). 3 months after treatment, CT value of the bone flare phenomena group and progressive disease group 1 changed when compared with before treatment, the differences were statistically signiifcant (t=-5.787 and-2.788,P<0.05) and there was no statistically signiifcant difference (t=1.691,P>0.05) of CT value in the progressive disease group 2 after 3 months' treatment. After 3 months' treatment, the bone flare phenomena group mostly appeared as osteogenic sclerosis of osteolytic lesions, while the cases of progressive disease group mostly appeared as new periosteal reaction of the lesion, or osteogenic/mixed lesion combined with osteolytic damages, the difference between the two groups was statistically signiifcant (χ2=10.139, 8.041 and 4.154,P<0.01,P<0.05). There was no statistically signiifcant difference in increase of density in osteosclerotic lesions (χ2=0.059, P>0.05).Conclusion In patients treated with ibandronate, when there is therapeutic effect evaluation standard of bone metastases (disease progression) and clinical comprehensive curative effect evaluation standard (effective) discordance at 3 months after treatment, it can be interpreted as bone flare phenomena, and the change of CT features contributes to the differential diagnosis of bone flare phenomena with progressive disease.